PRKDC and triple-negative breast carcinoma: In the context of triple-negative breast cancer heterogeneity, PRKDC has been reported to be highly expressed in the basal immune activated and basal immune-suppressed molecular subgroups, while being depleted in the luminal androgen receptor and mesenchymal breast carcinomas11.